<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="81953">
  <stage>Registered</stage>
  <submitdate>5/04/2007</submitdate>
  <approvaldate>17/10/2007</approvaldate>
  <actrnumber>ACTRN12607000532404</actrnumber>
  <trial_identification>
    <studytitle>A randomised trial to see if closing the arterial duct improves outcome in very premature babies</studytitle>
    <scientifictitle>Double blind randomised trial of the effect indomethacin for closure of patent ductus arteriosus on death and chronic lung disease in very preterm infants.
The Indomethacin Ductus Closure Effect trial: The INDUCE trial</scientifictitle>
    <utrn />
    <trialacronym>INDUCE trial</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Premature babies</healthcondition>
    <healthcondition>Patent ductus arteriosus</healthcondition>
    <healthcondition>Death</healthcondition>
    <healthcondition>Chronic lung disease</healthcondition>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Complications of newborn</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Intravenous indomethacin 200mcg/kg x1 then 100mcg/kg x5, all at 24 hourly intervals. Prepared as standard dilution so 0.4ml/kg given for 1st dose then 0.2ml/kg</interventions>
    <comparator>Placebo (intravenous saline) administered as same volume as indomethacin, 0.4ml/kg for 1st dose then 0.2ml/kg for remaining 5 doses, all at 24 hourly intervals.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Chronic lung disease</outcome>
      <timepoint>36 weeks post-menstrual age</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Death</outcome>
      <timepoint>36 weeks post-menstrual age</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Retinopathy</outcome>
      <timepoint>Retinal maturity (= vascularity progressed to zone 3).</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Intraventricular haemorrhage</outcome>
      <timepoint>Hospital discharge</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Necrotising enterocolitis</outcome>
      <timepoint>Hospital discharge</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>long term respiratory morbidity</outcome>
      <timepoint>2 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>neurodevelopmental outcome</outcome>
      <timepoint>2 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Birthweight &lt;1250g or gestational age &lt;28 weeks. Large patent ductus arterisous diagnosed by echocardiography at 3 days of age.</inclusivecriteria>
    <inclusiveminage>2</inclusiveminage>
    <inclusiveminagetype>Days</inclusiveminagetype>
    <inclusivemaxage>28</inclusivemaxage>
    <inclusivemaxagetype>Weeks</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Significant congenital anomalies, likely death within hours, previous indomethacin, contraindication to indomethacin.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Parental consent and then randomised. Indomethacin or placebo prepared in yellow coloured syringes (indomethacin is a yellowish solution) prepared by hospital pharmacy. The randomisation list has been prepared in blocks in random order. It is held by the Clinical Trials Unit of the Hospital Pharmacy and the Chair of the Data Safety Monitoring Committee. The list is not available to clinicians or investigators. Randomisation is by allocating the baby the next number and faxing a perscription to Pharmacy. Pharmacy line up the number with the randomisation list and prepare the drug. The Clinical Trials Unit in Pharmacy acts as the central randomisation site.</concealment>
    <sequence>Permuted block randomisation stratified above or below 27 weeks.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>10/08/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>90</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr David Knight</primarysponsorname>
    <primarysponsoraddress>Auckalnd City Hospital
Auckland
NZ</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>A+ trust</fundingname>
      <fundingaddress>Auckland City Hospital
Auckland</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Auckland Medical Research Foundation</fundingname>
      <fundingaddress>Auckland City Hospital 
Auckland</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Auckland City Hospital Research Review Committee</sponsorname>
      <sponsoraddress />
      <sponsorcountry>New Zealand</sponsorcountry>
    </secondarysponsor>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Patent ductus arteriosus is a common complication in very preterm infants. Although it is treated aggressively with indomethacin, there is little or no evidence that this treatment improves outcome in these infants. This is a pilot study to investigate if outcome is improved. If the pilot is successful, a large international trial will be organised.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>NZ Health and Disability Ethics Committees, Northern X Regional Ethics Committee</ethicname>
      <ethicaddress />
      <ethicapprovaldate>28/06/2007</ethicapprovaldate>
      <hrec>NTX/07/04/030</hrec>
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>David Knight</name>
      <address>Newborn Services
Auckland City Hospital
Park Rd
Auckland</address>
      <phone>+64 9 3074949</phone>
      <fax />
      <email>davidk@adhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>David Knight</name>
      <address>Newborn Services
Auckland City Hospital
Park Rd
Auckland</address>
      <phone>+64 9 3074949</phone>
      <fax />
      <email>davidk@adhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>David Knight</name>
      <address>Newborn Services
Auckland City Hospital
Park Rd
Auckland</address>
      <phone>+64 9 3074949</phone>
      <fax />
      <email>davidk@adhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>